Positron Introduces New Attrius(TM)
Cardiac PET Scanner at the Annual Meeting of the
American Society of Nuclear Cardiology
Wednesday October 17, 11:48 am ET
HOUSTON--(BUSINESS WIRE)--Positron Corporation
(OTCBB:POSC
-
News) introduced their new dedicated Cardiac PET
system at the annual meeting of the American Society
of Nuclear Cardiology. The meeting attendees
consisted of more than 1,500 nuclear cardiologists,
practice administrators and technologists with the
majority operating myocardial perfusion imaging with
private cardiology practices.Positron's new
Attrius(TM) molecular imaging system incorporates
patented and proprietary software and hardware
technology for the diagnosis and treatment of
patients with heart disease. Positron Corporation
offers a unique combination of low cost technology
and disease specific software solutions
differentiating themselves from all other medical
device manufacturers.
Positron's refocus on cardiology has taken them
back to their original core competency which is
providing cardiologists with superior imaging tools
combined with disease specific software solutions.
Market dynamics have changed dramatically since 1983
when the company offered their first cardiac device.
The proposed increase in reimbursement in the face
of the deficit reduction act, the introduction of
new peer reviewed literature suggesting the cost
effective benefit of cardiac PET imaging combined
with Positron's market entry of a cost effective PET
only solution are clear indications of new market
development.
Positron Corporation's President, Joseph Oliverio
stated, "The Attrius(TM) is the only dedicated
cardiac PET scanner on the market, which positions
the Company in a unique market ascendancy point.
Market dynamics combined with our cost effective
scanner offering will allow the Company to seize a
leading market position as a unique niche player in
the nuclear cardiology market segment with virtually
no other company offering such a comprehensive
solution."
About Positron
Positron Corporation designs, manufactures,
markets and supports advanced cardiac molecular
imaging devices utilizing single photon emission
computed tomography (SPECT) and positron emission
tomography (PET). The company's molecular imaging
systems incorporate patented and proprietary
software and hardware technology for the diagnosis
and treatment of patients with heart disease.
Positron Corporation offers unique combination of
low cost technology and disease specific software
solutions differentiating themselves from all other
medical device manufacturers. Additional information
may be found at
http://www.positron.com and
http://www.is2medical.com.
Forward Looking Statements:
Statements in this document contain certain
forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and the
Securities Exchange Act of 1934, as amended. These
statements are based on many assumptions and
estimates and are not guarantees of future
performance and may involve known and unknown risks,
uncertainties and other factors which may cause the
actual results, performance or achievements of
Positron Corporation to be materially different from
future results, performance or achievements
expressed or implied by such forward-looking
statements. The words "expect," "anticipate,"
"intend," "plan," "believe," "seek," "estimate," and
similar expressions are intended to identify such
forward-looking statements. Our actual results may
differ materially from the results anticipated in
these forward-looking statements due to a variety of
factors, including, without limitation those set
forth as "Risk Factors" in our filings with the
Securities and Exchange Commission.
For further information please contact Positron
Corporation at (281) 492-7587.
Contact:Positron Corporation
Joseph Oliverio, 866-613-7587
President
Source: Positron
Corporation
Main news page
|
